Clearmind Medicine Partners with Johns Hopkins for Psychedelic-Derived Therapeutic Trials

TEL AVIV— Clearmind Medicine Inc.  a biotech firm the charge in discovering and developing innovative psychedelic-derived treatments for significant health concerns, revealed a new collaboration today. The company has forged a Clinical Trial Agreement with the renowned Johns Hopkins University School of Medicine (JHU) to oversee its Phase I/IIa clinical evaluation of its proprietary MEAI-based drug, CMND-100.

Leading the research initiative is Dr. Jennifer Ellis, PhD, an Associate Professor of Psychiatry and Behavioral Sciences at JHU. She will receive vital backing from co-investigators, including Professor Eric Strain, the head of the Behavioral Pharmacology Research Unit at the JHU School of Medicine.

Expressing his enthusiasm for the partnership, Dr. Adi Zuloff-Shani, Clearmind’s CEO, remarked, “We are deeply honored to have JHU by our side as we embark on this groundbreaking human clinical trial. Their global reputation in psychedelic clinical research and addiction studies makes them an invaluable ally. With Johns Hopkins and the previously engaged Yale School of Medicine’s Department of Psychiatry, we’re privileged to collaborate with two of the world’s premier medical institutions.”

The current medical landscape sees a burgeoning interest in the potential of psychedelic compounds to tackle various neuropsychiatric conditions. Clearmind’s forthcoming Phase I/IIa trial, labeled CM-CMND-001, primarily seeks to ascertain the tolerable dosage and delineate the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and successive doses of CMND-100. This assessment will target both healthy individuals and those grappling with Alcohol Use Disorder (AUD). A secondary objective aims to gauge the effectiveness of CMND-100 in curtailing drinking habits and curbing cravings in those diagnosed with moderate-to-severe AUD. Participants in the trial will consume oral capsules daily for a ten-day stretch, and will subsequently record their alcohol (and cigarette) cravings and consumption patterns throughout the evaluation period.

Characterized as a multinational, multi-center endeavor, the CM-CMND-001 clinical trial will methodically explore the safety, tolerability, and pharmacokinetic properties of CMND-100 in both healthy volunteers and subjects with AUD.